InvestorsHub Logo
Followers 99
Posts 5356
Boards Moderated 0
Alias Born 08/27/2011

Re: Protector post# 247475

Tuesday, 01/05/2016 7:21:11 AM

Tuesday, January 05, 2016 7:21:11 AM

Post# of 345969
Of course the first look will address futility does Bavituximab do something? If the doce taxol arm is trending better then the Bavituximab arm the DMC will recommend stopping trial. Simple as that.

If the Bavituximab arm is overwhelmingly extending life at the first look the DMC may recommend giving all patients Bavituximab.

If the trial is safe and trending as planned the DMC will recommend continuing trial.

Bavituximab the essential key to a cure for cancer needed by all pharmaceutical companies.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News